Palvella Therapeutics, Inc. (PVLA) stock analysis
PVLA · Palvella Therapeutics, Inc.
Latest recorded price: USD 144.60
Sector and industry: Healthcare · Biotechnology
Fiscal 2023 figures: revenue growth 13.4%, free cash flow margin -126.1%. The model flags 2 risk signals for this company (1 high severity).
Similar companies in Healthcare
- Ultragenyx Pharmaceutical Inc. - Common Stock (RARE)
- Arcus Biosciences, Inc. (RCUS)
- Regeneron Pharmaceuticals, Inc. - Common Stock (REGN)
- Relay Therapeutics, Inc. (RLAY)
- Roivant Sciences Ltd. (ROIV)
- Royalty Pharma plc (RPRX)
- Revolution Medicines, Inc. (RVMD)
- Recursion Pharmaceuticals, Inc. - Class A Common Stock (RXRX)